Table 2.
Univariate and multivariate Cox regression analysis for PFS and OS for patients treated with R‐CHOP/21 as first‐line therapeutic strategy (n = 203)
| Characteristics | Progression‐free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| Univariate | Multivariate | HR (95% CI) | Univariate | Multivariate | HR (95% CI) | |
| Female/male | 0.010 | NS | – | 0.569 | – | – |
| Stage IV‐ non BMI | 0.583 | – | – | 0.755 | – | – |
| Age > 60 | 0.018 | NS | – | 0.004 | 0.010 | 2.4 (1.2–4.8) |
| ECOG PS (>1) | <0.001 | 0.003 | 2.9 (1.5–6.0) | <0.001 | 0.017 | 2.4 (1.2–5.0) |
| B2microglobulin [ULN]a | 0.017 | NS | – | <0.001 | 0.040 | 2.2 (1.0–4.5) |
| Extranodal‐Non BMI (>1 site) | 0.370 | – | – | 0.268 | – | – |
| LDH [ULN]a | 0.124 | NS | – | 0.005 | NS | – |
| Bulky mass [≥10 cm] | 0.151 | – | – | 0.504 | – | – |
| BMI by PET/CT | 0.121 | NS | – | 0.018 | NS | – |
| BMI by BMB | <0.001 | 0.001 | 3.6 (1.7–7.6) | 0.326 | – | – |
Numbers in red: P < 0.05; blue: P ≤ 0.15. ECOG PS, Eastern cooperative oncology group performance score; LDH, lactate dehydrogenase; ULN, upper limit of normal (1B2microglobulin > 2.5 mg/L and 2LDH > 250 UI/L); BMI, bone marrow involvement; BMB, bone marrow biopsy; PET/CT, positron emission tomography/computed tomography; NS, no significance.